January 2008 in “The Year book of endocrinology” Gene variant linked to prostate cancer, hormone levels, and hair loss.
6 citations
,
May 2008 in “Current Opinion in Oncology” 2007 research improved understanding of prostate cancer risk, diagnosis, and treatment, but also showed the need for personalized treatment and further study on certain therapies' risks.
3 citations
,
October 2011 in “QJM” The drugs finasteride and dutasteride reduce low-grade prostate cancers but may double the risk of high-grade cancers.
August 2008 in “Current Opinion in Internal Medicine” In 2007, prostate cancer research improved understanding of risk, diagnosis, and treatment, but also showed heart risks with certain therapies and the need for personalized care.
72 citations
,
January 2003 in “American Journal of Pathology” A protein called CBP is found in prostate cancer and can increase the effectiveness of certain prostate cancer treatments.
57 citations
,
January 1986 in “The Prostate” The document suggests that targeting the hormone DHT could be a more effective treatment for prostate cancer than targeting testosterone.
38 citations
,
February 2011 in “Annals of Oncology” Men who experienced baldness at age 20 may have double the risk of getting prostate cancer.
34 citations
,
February 2013 in “Journal of The American Academy of Dermatology” Vertex pattern hair loss linked to higher prostate cancer risk.
22 citations
,
August 2014 in “Clinical endocrinology” Taking finasteride for benign prostate hyperplasia may increase the risk of osteoporosis, especially at higher doses.
14 citations
,
June 2015 in “Toxicology and Industrial Health” Low doses of BPA can increase prostate growth and change hormone levels in adult rats.
7 citations
,
October 2017 in “The Prostate” Baldness in men with prostate cancer is linked to higher levels of certain sex hormones, but chest hair density is not.
2 citations
,
May 2024 in “The World Journal of Men s Health” Dutasteride and finasteride have similar effects on prostate cancer risk in BPH patients.
1 citations
,
May 2023 in “Jurnal Kedokteran Diponegoro” Chemotherapy for prostate, bladder, and testicular cancer patients commonly causes hair loss, fatigue, and decreased appetite.
1 citations
,
December 2013 in “Urological Science” A man developed male breast cancer after four years of finasteride treatment for an enlarged prostate.
May 2024 in “KIU journal of health science” Kolaviron and quercetin may help treat prostate issues.
January 2023 in “International Journal of Clinical and Medical Education Research” Correct testosterone levels for age to treat prostate cancer, using low dose treatments as necessary.
April 2022 in “Indian Journal of Forensic Medicine & Toxicology” PSA can help diagnose high androgen levels in women.
February 2017 in “Cancer Causes & Control” Swedish men with the E213 A-allele of the androgen receptor have a lower risk of prostate cancer.
December 2010 in “Actas Urológicas Españolas” Taking dutasteride for one month before prostate surgery can reduce bleeding.
October 2008 in “The Journal of Urology” Finasteride reduces prostate cancer risk but may increase high-grade tumors and has side effects; biopsy methods have similar outcomes; psychosocial factors affect sexual recovery post-surgery.
January 2006 in “Actas Urológicas Españolas” Incidental prostate cancer was found in 4.89% of patients undergoing surgery for benign prostatic hyperplasia.
71 citations
,
September 2007 in “Cancer” Prostate cancer prevention includes diet changes, supplements, and medications, with more answers expected soon.
2 citations
,
January 2011 in “Clinical medicine insights” Dutasteride is effective for treating prostate enlargement and reducing related surgery risk, but is not approved for preventing prostate cancer.
Certain plasma proteins are linked to prostate cancer risk and could help in early detection and treatment.
4 citations
,
October 2002 in “BJUI” Finasteride treats hair loss but may affect prostate cancer detection.
1 citations
,
January 2019 in “PubMed” Baldness score can't be used to predict prostate size.
148 citations
,
April 2009 in “Molecular Pharmaceutics” Researchers developed promising agents for prostate cancer imaging, with the best one showing high potential for clinical use.
72 citations
,
April 2008 in “The Journal of urology/The journal of urology” Dutasteride and finasteride do not significantly affect bone density, blood fats, or blood production, but slightly lower PSA levels and minimally impact sexual function in healthy young men.
49 citations
,
August 2009 in “British Journal of Cancer” Finasteride might lower the risk of low-grade prostate cancer but not high-grade cancer, while alpha-blockers might reduce high-grade cancer risk.
44 citations
,
October 2010 in “BJUI” 5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.